Jain PharmaBiotech, Feb 2012, Pages: 639
innovative methods of drugdelivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor
Arrowhead Publishers, Sep 2008, Pages: 283
Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drugdeliveryindustry and its application to both the pharmaceutical and biotech industries. While the sector
Jain PharmaBiotech, Feb 2012, Pages: 772
with autonomous operation guided by the needs.
Nanomedicine is now within the realm of reality starting with nanodiagnostics and drugdelivery facilitated by nanobiotechnology. Miniature devices such as nanorobots
Arrowhead Publishers, May 2006, Pages: 233
mechanisms. Thus, post patent expiry sales can be switched from the ethical manufacturer to the drugdelivery sector.
The GlobalDrugDelivery Market: Research Trends and Market Outlook is an up-to-date guide
Cientifica Ltd., Nov 2011, Pages: 212
and the market forces at work in the pharmaceutical industry, where patents expire after a relatively short period of time unless a novel form of drugdelivery is developed that will extend the patent, are two major
Cientifica Ltd., Sep 2007, Pages: 301
industry with an eye towards how nanoparticle drugdelivery technology will impact the economics of the pharmaceutical market.
The information includes business summaries, technology core competencies, how
JZMed Inc., May 2011, Pages: 230
and in-depth comparisons of the drug formulation industries between China and India. It has revealed the relative positions of China and India in the global pharmaceutical supply chain.
- The report also
Avalon Global Research, Oct 2010, Pages: 20
delivery mode in place of oral formulations. Relatively high insulation from competition post off- patent stage, strong entry barriers, high profit margin and drug effectiveness are making injectables more
Global Industry Analysts, Inc., Sep 2011, Pages: 391
A Brief Insight into the Drug Eluting Stents Market 16
Table 4: GlobalDrug-Eluting Stents Market by Product Type
(2010): Percentage Breakdown of Unit Sales and Revenues
Cientifica Ltd., June 2008, Pages: 1027
Case Study – Cytrx’s Rnai Nanoparticle Delivery Technology For
Rnai Therapeutics
Investing In Nanopartcle-Enabled DrugDeliveryIndustry
Case Study – Nanotherapeutics’ Commercialisation Strategy
Jain PharmaBiotech, Feb 2012, Pages: 780
methylation
Role of molecular imaging in personalized therapy of cancer
Functional diffusion MRI
FDG-PET/CT for personalizing cancer treatment
Image-guided personalized drugdelivery in cancer
Tumor
Spectra Intelligence, Oct 2009, Pages: 81
&D pipeline for addiction disorders
- Guide to leads for potential licensing opportunities
About the Author
Tim Atkinson has authored over 30 pharmaceutical market research reports and has expertise in drug
Jain PharmaBiotech, Feb 2012, Pages: 1008
by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drugdelivery, tissue
Axis Research Mind, Feb 2011, Pages: 647
.
Global interventional cardiac devices industry forecasts to reach at US$15.7 billion by 2015 at a high CAGR of 9.9% during the analysis period 2009-2015. The North American segment accounts for nearly 35
Axis Research Mind, Feb 2011, Pages: 412
for guiding catheters market value indicate 55% by 2015 leaving the rest of the market to the angiography catheters, inflation and accessories.
Report Focus:
The report ‘Global Cardiac Catheters
Global Markets Direct, Sep 2009, Pages: 69
DrugDelivery Technologies
12.2 Product News
12.2.1 Jun 15, 2007: OptiNose Announces The Initiation Of Phase II Study In Chronic Rhinosinusitis
13 Appendix
13.1 Global Markets Direct
Global Industry Analysts, Inc., June 2010, Pages: 492
) II-6
Drug-Eluting Stents Market Bounces Back II-6
Cypher And Taxus Dominate Global DES Market II-6
Drug Eluting Stent System
Bioplan Associates Inc., April 2008, Pages: 190
for the UK economy. Ignazio has also worked on a number of other industry related initiatives with the ABPI, NHS, R&D Forums and UKCRN.
Ms. Sue Green has worked in global regulatory affairs for over 17 years
Jain PharmaBiotech, Feb 2012, Pages: 214
development
Use of microarrays in clinical trials
Reverse phase protein microarrays
Controlled-release microchip for drugdelivery
8. Biochips for Biomarkers, Molecular Diagnostics & Personalized Medicine
Business Insights, June 2007, Pages: 244
industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies
